pociredir (an investigational drug)

Action and Spectrum

Actions and spectrum:  

Pociredir works by stimulating the expression of fetal hemoglobin. It is an inhibitor of polycomb repressive complex 2 class. 

Drug Interaction

Adverse Reaction

None 

Black Box Warning

Black Box warning  

None  

Contraindication / Caution

Contraindication/Caution:  

None  

Pregnancy / Lactation

Pregnancy Warnings: 

Pregnancy category: N/A 

Lactation: Excretion of the drug into the human breast milk is unknown 

Pregnancy categories: 

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester. 

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women. 

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology:  

Pociredir is an antianemia agent.  It belongs to the allosteric PRC2 inhibitor (EED) class.  

Pharmacodynamics:  

Pociredir is designed to induce fetal hemoglobin expression. This is used to compensate mutated adult hemoglobin in sickle cell disease.  

Pharmacokinetics:  

Limited information is available on ADME.    

Adminstartion

Administration:  

The route of administration is not fully known.  

Patient Information Leaflet

Patient information leaflet  

Generic Name: pociredir  

Why do we use pociredir?  

Pociredir is an inhibitor of EED (embryonic ectoderm development). It is under investigation for its treatment in sickle cell disease.